Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Pfizer Inc. PFE

Alternate Symbol(s):  N.PFE

Healthcare Drug Manufacturers - Major
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 
1 2 3 4 5 6 Next
The Market Herald's Weekly Cannabis Report
posted July 01, 2022 09:00 am by Dave Jackson
Affinor Growers (CSE:AFI) announces $2 million private placementSource: Affinor Growers Inc.Affinor Growers Inc. (CSE.AFI, OTCQB: RSSFF, Forum) is undertaking a private placeme... read article.
@ the Bell: Summer blues for TSX, Wall Street sees worst half since 1970
posted June 30, 2022 04:17 pm by Jon Brown
On the last day before the Canada Day long weekend, the TSX finished lower by triple digits in broad-based decline as commodity prices fell. Energy and base metals led decliners, while near 20 per... read article.
Buzz on the Bullboards: Sizzling sector highlights
posted June 30, 2022 08:50 am by Jon Brown
It has been a sizzling few days recently for most of North America, both weather-wise and for investing discussions. The markets face a rate hike in the U.S., ongoing inflation, rising oil and... read article.

New Press Release - Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID(TM)

posted June 30, 2022 06:46 am  by  PressRelease
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk for progression to severe illness from COVID-19; consistent with current emergency use authorizationFinal results from EPIC-HR study showed an 86% reduction in relative risk of...read article.

New Press Release - Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

posted June 28, 2022 06:00 am  by  PressRelease
Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful resultsPriovant is developing brepocitinib in severe autoimmune diseases...read article.

New Press Release - Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

posted June 25, 2022 10:00 am  by  PressRelease
Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase against OmicronGeometric mean ratios...read article.

New Press Release - Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts

posted June 24, 2022 10:00 am  by  PressRelease
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Thursday, July 28, 2022. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second...read article.

New Press Release - Pfizer Declares Third-Quarter 2022 Dividend

posted June 23, 2022 10:35 am  by  PressRelease
Board of Directors approves quarterly cash dividend of $0.40 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.40 third-quarter 2022 dividend on the company’s common stock, payable September 6, 2022, to holders of the Common Stock of record at the close...read article.

New Press Release - Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

posted June 20, 2022 01:00 am  by  PressRelease
Pfizer will invest €90.5 million in ValnevaPlanned Phase 3 study confirmed to initiate in Q3 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into an Equity Subscription Agreement and have updated...read article.

New Press Release - Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain

posted June 17, 2022 06:45 am  by  PressRelease
BASEL, Switzerland and NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that results of the Phase 3 SPIRIT 1 and SPIRIT 2 studies of investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg...read article.

New Press Release - Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million

posted June 16, 2022 07:00 am  by  PressRelease
$25 Million Equity Investment by Pfizer at $9.90 Per Share Term Loan Facility from Hercules Providing Up to $100 MillionIf Fully Drawn, Akero Cash Runway Extended One Full Year From Previously Announced Q3 2023 to Q3 2024SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Akero...read article.

New Press Release - Pfizer Reports Additional Data on PAXLOVID(TM) Supporting Upcoming New Drug Application Submission to U.S. FDA

posted June 14, 2022 04:32 pm  by  PressRelease
In the EPIC-SR study of PAXLOVID™(nirmatrelvir [PF-07321332] tablets and ritonavir tablets), the novel primary endpoint of self-reported, sustained alleviation of all symptoms for four consecutive days was not met, as previously reportedData from standard-risk patients, both vaccinated and...read article.

New Press Release - Pfizer Completes Acquisition of ReViral

posted June 09, 2022 10:02 am  by  PressRelease
Acquisition expands Pfizer’s anti-infective pipeline and reinforces commitment to developing both medicines and vaccines to help combat respiratory syncytial virus (RSV) Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of ReViral, a privately held, clinical...read article.

New Press Release - Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

posted June 09, 2022 09:01 am  by  PressRelease
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical, at the Storebrand Conference: Invest in the Future on Thursday, June 16, 2022...read article.

New Press Release - Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

posted June 08, 2022 10:05 am  by  PressRelease
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer, President, Worldwide Research, Development and Medical, and William Pao, Chief Development Officer, Executive Vice President, at the...read article.

New Press Release - Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.

posted June 06, 2022 11:02 am  by  PressRelease
Expansion will create more than 250 additional high-skilled manufacturing jobs at Pfizer’s Kalamazoo site Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility...read article.

New Press Release - Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer

posted June 04, 2022 08:01 am  by  PressRelease
Pfizer Inc. (NYSE:PFE) today announced overall survival (OS) results from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE® (palbociclib) in combination with letrozole compared to placebo plus letrozole for the first-line treatment of postmenopausal women with estrogen receptor-positive (ER+),...read article.

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

posted June 03, 2022 03:58 am  by  TaylorSwifft (0)
FSD Pharma ready to proceed with Phase 2 clinical trial of FSD...read more

New Press Release - Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®

posted June 02, 2022 06:50 am  by  PressRelease
BASEL, Switzerland and NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1...read article.

FSD Pharma Files Investigational New Drug Application “IND”

posted June 01, 2022 11:18 pm  by  TaylorSwifft (0)
   rate and reply

New Press Release - Pfizer Provides Update on Ownership Interest in Haleon

posted June 01, 2022 08:27 am  by  PressRelease
Haleon to Become a Publicly Listed Standalone Company in July Following a Demerger by GSKPost-Demerger, Pfizer Plans to Exit Ownership Interest in Haleon in a Disciplined Manner with the Objective to Maximize Value for Pfizer Shareholders Pfizer Inc. (NYSE: PFE) today provided an update on its...read article.

New Press Release - Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability

posted May 31, 2022 10:01 am  by  PressRelease
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a live webcast at 3:45 p.m. EDT on Monday, June 6, 2022, with Angela Hwang, Group President, Pfizer Biopharmaceuticals Group, and Aamir Malik, Chief Business Innovation Officer, Executive Vice President, who...read article.

RE:Whole Numbers

posted May 29, 2022 10:36 am  by  Joe455 (27565)
?  rate and reply
1 2 3 4 5 6 Next